Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Three-month primary efficacy data for the SUCCESS Trial; a phase III, multi-center, prospective, randomized, controlled study treating female stress urinary incontinence with the vesair intravesical balloon.

McCammon K, Jacoby K, Kalota S, Snyder J, Cline K, Robertson K, Rardin C, Kahan R, Green L, Zuckerman J, Rovner E.

Neurourol Urodyn. 2017 Nov 2. doi: 10.1002/nau.23324. [Epub ahead of print]

PMID:
29095516
2.

Twelve-Month Efficacy and Safety Data for the "Stress Incontinence Control, Efficacy and Safety Study": A Phase III, Multicenter, Prospective, Randomized, Controlled Study Treating Female Stress Urinary Incontinence Using the Vesair Intravesical Balloon.

Winkler H, Jacoby K, Kalota S, Snyder J, Cline K, Robertson K, Kahan R, Green L, McCammon K, Rovner E, Rardin C.

Female Pelvic Med Reconstr Surg. 2017 Sep 26. doi: 10.1097/SPV.0000000000000488. [Epub ahead of print]

PMID:
28953076
3.

Type 1 and 2 Myocardial Infarction and Myocardial Injury: Clinical Transition to High-Sensitivity Cardiac Troponin I.

Sandoval Y, Smith SW, Sexter A, Thordsen SE, Bruen CA, Carlson MD, Dodd KW, Driver BE, Hu Y, Jacoby K, Johnson BK, Love SA, Moore JC, Schulz K, Scott NL, Apple FS.

Am J Med. 2017 Dec;130(12):1431-1439.e4. doi: 10.1016/j.amjmed.2017.05.049. Epub 2017 Jul 21.

PMID:
28739197
4.

Diagnostic Performance of High Sensitivity Compared with Contemporary Cardiac Troponin I for the Diagnosis of Acute Myocardial Infarction.

Sandoval Y, Smith SW, Thordsen SE, Bruen CA, Carlson MD, Dodd KW, Driver BE, Jacoby K, Johnson BK, Love SA, Moore JC, Sexter A, Schulz K, Scott NL, Nicholson J, Apple FS.

Clin Chem. 2017 Oct;63(10):1594-1604. doi: 10.1373/clinchem.2017.272930. Epub 2017 Jul 12.

PMID:
28701316
5.

Angiotensin II for the Treatment of Vasodilatory Shock.

Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hästbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM; ATHOS-3 Investigators.

N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21.

PMID:
28528561
6.

Measuring and predicting the diffraction properties of cylindrically bent potassium acid phthalate, KAP(001), crystals.

Haugh MJ, Jacoby KD.

Rev Sci Instrum. 2017 Feb;88(2):023113. doi: 10.1063/1.4975775.

PMID:
28249466
7.

Characterization of homing endonuclease binding and cleavage specificities using yeast surface display SELEX (YSD-SELEX).

Jacoby K, Lambert AR, Scharenberg AM.

Nucleic Acids Res. 2017 Feb 17;45(3):e11. doi: 10.1093/nar/gkw864.

8.

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group.

J Urol. 2017 Feb;197(2S):S216-S223. doi: 10.1016/j.juro.2016.10.109. Epub 2016 Dec 22.

PMID:
28012773
9.

A technique for measuring the quality of an elliptically bent pentaerythritol [PET(002)] crystal.

Haugh MJ, Jacoby KD, Barrios MA, Thorn D, Emig JA, Schneider MB.

Rev Sci Instrum. 2016 Nov;87(11):11D612.

PMID:
27910647
10.

Discordance between ICD-Coded Myocardial Infarction and Diagnosis according to the Universal Definition of Myocardial Infarction.

Díaz-Garzón J, Sandoval Y, Smith SW, Love S, Schulz K, Thordsen SE, Johnson BK, Driver B, Jacoby K, Carlson MD, Dodd KW, Moore J, Scott NL, Bruen CA, Hatch R, Apple FS.

Clin Chem. 2017 Jan;63(1):415-419. doi: 10.1373/clinchem.2016.263764. Epub 2016 Nov 3.

PMID:
27811209
11.

Measuring the diffraction properties of an imaging quartz(211) crystal.

Haugh MJ, Jacoby KD, Koch JA, Chen H, Hill KW, Schneider MB.

Rev Sci Instrum. 2016 Jun;87(6):063103. doi: 10.1063/1.4952746.

PMID:
27370422
12.

High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins.

Gwiazda KS, Grier AE, Sahni J, Burleigh SM, Martin U, Yang JG, Popp NA, Krutein MC, Khan IF, Jacoby K, Jensen MC, Rawlings DJ, Scharenberg AM.

Mol Ther. 2016 Sep 29;24(9):1570-80. doi: 10.1038/mt.2016.105. Epub 2016 May 16.

13.

pEVL: A Linear Plasmid for Generating mRNA IVT Templates With Extended Encoded Poly(A) Sequences.

Grier AE, Burleigh S, Sahni J, Clough CA, Cardot V, Choe DC, Krutein MC, Rawlings DJ, Jensen MC, Scharenberg AM, Jacoby K.

Mol Ther Nucleic Acids. 2016 Apr 19;5:e306. doi: 10.1038/mtna.2016.21.

14.

Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.

Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, De Ridder D, Jenkins B, Magyar A, Chapple C; 191622-096 Investigators.

J Urol. 2016 Sep;196(3):791-800. doi: 10.1016/j.juro.2016.03.146. Epub 2016 Mar 30.

PMID:
27038769
15.

Measuring the x-ray resolving power of bent potassium acid phthalate diffraction crystals.

Haugh MJ, Wu M, Jacoby KD, Loisel GP.

Rev Sci Instrum. 2014 Nov;85(11):11D619. doi: 10.1063/1.4891919.

PMID:
25430195
16.

Homing endonuclease target determination using SELEX adapted for yeast surface display.

Jacoby K, Scharenberg AM.

Methods Mol Biol. 2014;1123:165-90. doi: 10.1007/978-1-62703-968-0_13.

PMID:
24510268
17.

OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group.

J Urol. 2013 Jun;189(6):2186-93. doi: 10.1016/j.juro.2012.12.022. Epub 2012 Dec 14.

PMID:
23246476
18.

Integrated x-ray reflectivity measurements of elliptically curved pentaerythritol crystals.

Haugh MJ, Regan SP, Jacoby KD, Ross PW, Magoon J, Barrios MA, Emig JA, Shoup MJ 3rd, Fournier KB.

Rev Sci Instrum. 2012 Oct;83(10):10E122. doi: 10.1063/1.4738748.

PMID:
23126944
19.

Coupling endonucleases with DNA end-processing enzymes to drive gene disruption.

Certo MT, Gwiazda KS, Kuhar R, Sather B, Curinga G, Mandt T, Brault M, Lambert AR, Baxter SK, Jacoby K, Ryu BY, Kiem HP, Gouble A, Paques F, Rawlings DJ, Scharenberg AM.

Nat Methods. 2012 Oct;9(10):973-5. doi: 10.1038/nmeth.2177. Epub 2012 Sep 2.

20.

Expanding LAGLIDADG endonuclease scaffold diversity by rapidly surveying evolutionary sequence space.

Jacoby K, Metzger M, Shen BW, Certo MT, Jarjour J, Stoddard BL, Scharenberg AM.

Nucleic Acids Res. 2012 Jun;40(11):4954-64. doi: 10.1093/nar/gkr1303. Epub 2012 Feb 14.

Supplemental Content

Loading ...
Support Center